Industry Focus

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.

Direct download: 150520_IF_Healthcare.mp3
Category:Podcast -- posted at: 4:09pm EST